Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff(Translational Genomics Research Institute), Markus F. Renschler(Princess Margaret Cancer Centre), Sergei Tjulandin, Josep Tabernero(Deaconess Hospital), E. Gabriela Chiorean(University of Washington), Wen Wee(Roswell Park Comprehensive Cancer Center), Daniel A. Laheru(Bloomberg (United States)), Francis P. Arena, Thomas J. Ervin(Bayfront Medical Center), José Iglesias(Bionomics (Australia)), Xinyu Wei, Nathan Bahary(University of Pittsburgh Medical Center), Marion Harris(Centro Oncológico de Galicia), Manuel Hidalgo(Hospital Universitario de Fuenlabrada), Mansoor N. Saleh(Georgia Cancer Specialists), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Jeffrey R. Infante(Cancer Research Center), Thomas E. Seay, Scot Dowden, David Goldstein(Center for Discovery), Michele Reni(San Raffaele University of Rome), Ramesh K. Ramanathan(Ironwood Pharmaceuticals (United States)), Malcolm J. Moore(University Health Network)
Cited by 6,644
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k